Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 184

Cited In for PubMed (Select 4964084)

1.

Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.

Ciechanover A, Kwon YT.

Exp Mol Med. 2015 Mar 13;47:e147. doi: 10.1038/emm.2014.117. Review.

2.

Biochemical insight into the prion protein family.

Ciric D, Rezaei H.

Front Cell Dev Biol. 2015 Feb 11;3:5. doi: 10.3389/fcell.2015.00005. eCollection 2015. Review.

3.

Yeast prions: structure, biology, and prion-handling systems.

Wickner RB, Shewmaker FP, Bateman DA, Edskes HK, Gorkovskiy A, Dayani Y, Bezsonov EE.

Microbiol Mol Biol Rev. 2015 Mar;79(1):1-17. doi: 10.1128/MMBR.00041-14.

PMID:
25631286
4.

The standard scrapie cell assay: development, utility and prospects.

van der Merwe J, Aiken J, Westaway D, McKenzie D.

Viruses. 2015 Jan 16;7(1):180-98. doi: 10.3390/v7010180. Review.

5.

Prions and prion-like pathogens in neurodegenerative disorders.

Peggion C, Sorgato MC, Bertoli A.

Pathogens. 2014 Feb 18;3(1):149-63. doi: 10.3390/pathogens3010149. Review.

6.

Self-propagative replication of Aβ oligomers suggests potential transmissibility in Alzheimer disease.

Kumar A, Pate KM, Moss MA, Dean DN, Rangachari V.

PLoS One. 2014 Nov 3;9(11):e111492. doi: 10.1371/journal.pone.0111492. eCollection 2014.

7.

Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.

Sandberg MK, Al-Doujaily H, Sharps B, De Oliveira MW, Schmidt C, Richard-Londt A, Lyall S, Linehan JM, Brandner S, Wadsworth JD, Clarke AR, Collinge J.

Nat Commun. 2014 Jul 9;5:4347. doi: 10.1038/ncomms5347.

8.

Amyloid oligomers and protofibrils, but not filaments, self-replicate from native lysozyme.

Mulaj M, Foley J, Muschol M.

J Am Chem Soc. 2014 Jun 25;136(25):8947-56. doi: 10.1021/ja502529m. Epub 2014 Jun 12.

9.

Prions: generation and spread versus neurotoxicity.

Halliday M, Radford H, Mallucci GR.

J Biol Chem. 2014 Jul 18;289(29):19862-8. doi: 10.1074/jbc.R114.568477. Epub 2014 May 23. Review.

10.

Prions and prion-like proteins.

Fraser PE.

J Biol Chem. 2014 Jul 18;289(29):19839-40. doi: 10.1074/jbc.R114.583492. Epub 2014 May 23. Review.

PMID:
24860092
11.

Supersaturation-limited amyloid fibrillation of insulin revealed by ultrasonication.

Muta H, Lee YH, Kardos J, Lin Y, Yagi H, Goto Y.

J Biol Chem. 2014 Jun 27;289(26):18228-38. doi: 10.1074/jbc.M114.566950. Epub 2014 May 20.

12.

Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.

Ferreira NC, Marques IA, Conceição WA, Macedo B, Machado CS, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, Nunes RJ, Hughson AG, Raymond LD, Pascutti PG, Caughey B, Cordeiro Y.

PLoS One. 2014 Jan 6;9(1):e84531. doi: 10.1371/journal.pone.0084531. eCollection 2014.

13.

Small-molecule theranostic probes: a promising future in neurodegenerative diseases.

Aulić S, Bolognesi ML, Legname G.

Int J Cell Biol. 2013;2013:150952. doi: 10.1155/2013/150952. Epub 2013 Nov 12. Review.

14.

D-polyglutamine amyloid recruits L-polyglutamine monomers and kills cells.

Kar K, Arduini I, Drombosky KW, van der Wel PC, Wetzel R.

J Mol Biol. 2014 Feb 20;426(4):816-29. doi: 10.1016/j.jmb.2013.11.019. Epub 2013 Nov 28.

15.

Spontaneous generation of infectious prion disease in transgenic mice.

Torres JM, Castilla J, Pintado B, Gutiérrez-Adan A, Andréoletti O, Aguilar-Calvo P, Arroba AI, Parra-Arrondo B, Ferrer I, Manzanares J, Espinosa JC.

Emerg Infect Dis. 2013 Dec;19(12):1938-47. doi: 10.3201/eid1912.130106.

16.

From prion diseases to prion-like propagation mechanisms of neurodegenerative diseases.

Acquatella-Tran Van Ba I, Imberdis T, Perrier V.

Int J Cell Biol. 2013;2013:975832. doi: 10.1155/2013/975832. Epub 2013 Oct 10. Review.

17.

Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice expressing homologous prion protein.

Asante EA, Linehan JM, Smidak M, Tomlinson A, Grimshaw A, Jeelani A, Jakubcova T, Hamdan S, Powell C, Brandner S, Wadsworth JD, Collinge J.

PLoS Pathog. 2013;9(9):e1003643. doi: 10.1371/journal.ppat.1003643. Epub 2013 Sep 26.

18.

Laboratory activities involving transmissible spongiform encephalopathy causing agents: risk assessment and biosafety recommendations in Belgium.

Leunda A, Van Vaerenbergh B, Baldo A, Roels S, Herman P.

Prion. 2013 Sep-Oct;7(5):420-33. doi: 10.4161/pri.26533. Epub 2013 Sep 20. Review.

19.

Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.

Silva JL, Rangel LP, Costa DC, Cordeiro Y, De Moura Gallo CV.

Biosci Rep. 2013 Jul 25;33(4). pii: e00054. doi: 10.1042/BSR20130065. Review.

20.

Ethics in prion disease.

Bechtel K, Geschwind MD.

Prog Neurobiol. 2013 Nov;110:29-44. doi: 10.1016/j.pneurobio.2013.07.001. Epub 2013 Jul 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk